NEW YORK, March 13, 2015 /PRNewswire/ -- Faruqi &
Faruqi, LLP, a leading national securities law firm, is
investigating potential securities fraud at AcelRx Pharmaceuticals,
Inc. ("AcelRx" or the "Company") (NasdaqGM: ACRX).
The investigation focuses on whether the Company and its
executives violated federal securities laws by making materially
false and misleading statements regarding the Company's business,
operations, and prospects.
On March 9, 2015, AcelRx announced
that it has received correspondence from the United States Food and
Drug Administration advising that, in addition to the bench testing
and Human Factor studies it has performed for its drug Zalviso, the
New Drug Application for Zalviso will require a new clinical study
to assess the risk of inadvertent dispensing and the overall risk
of dispensing failures.
Following this news, AcelRx stock declined by $3.23 per share, or nearly 37%, to close on
March 9, 2015 at $5.51 per share.
Request more information now by clicking here:
www.faruqilaw.com/ACRX. There is no cost or obligation to
you.
Take Action
If you invested in AcelRx stock or options through March 8, 2015 and would like to discuss your
legal rights, visit www.faruqilaw.com/ACRX. You can also
contact us by calling Richard
Gonnello toll free at 877-247-4292 or at 212-983-9330 or by
sending an e-mail to rgonnello@faruqilaw.com. Faruqi &
Faruqi, LLP also encourages anyone with information regarding
AcelRx's conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
We welcome the opportunity to discuss your particular case.
All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello,
Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-acelrx-pharmaceuticals-inc-acrx-to-contact-the-firm-300050419.html
SOURCE Faruqi & Faruqi, LLP